BioMedNewsBreaks

WednesdayApr 12, 2023 2:33 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Provides Update on Spin-Out Plan, Announces Shareholder Meeting

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, plans to complete its spin-out transaction outlined in a plan of arrangement. The plan called for shares of the yet-to-be-formed wholly owned subsidiary to be separated into an independent public company. According to the announcement, the transaction is slated to be complete in July 2023 and is designed to enable FSD Pharma to focus on developing core assets and maximizing shareholder value. The company noted that, as of…

Continue Reading

MondayApr 10, 2023 1:15 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls Over 100 Patients in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that more than 100 patients have been enrolled in the company’s potentially pivotal study with its lead product candidate, Berubicin. “We have long promised a study with a robust sample size sufficient to effectively determine Berubicin’s therapeutic potential,” said John Climaco, CEO of CNS Pharmaceuticals. “Today’s achievement shows we are doing just that. Enrolling over 100 patients in this relatively rare disease in a little more than 18 months is a remarkable…

Continue Reading

ThursdayApr 06, 2023 12:48 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Adds Italy to Growing Portfolio of Countries for Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP) today announced its receipt of approval from the Italian Medicines Agency (“AIFA”) Competent Authority and the A.O.U. Policlinico di Bari Ethics Committee for its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. According to the update, the company plans to open its clinical sites in Italy imminently in addition to the previously opened 41 clinical trial sites of the 60 selected across the U.S., France, Spain, and Switzerland. “Our team has continued to make dedicated efforts to build momentum and drive…

Continue Reading

TuesdayApr 04, 2023 11:58 am

BioMedNewsBreaks – Progressive Care Inc. (RXMD) Releases 2022 Annual Financial Results, Reports $40.6M Total Revenue

Progressive Care (OTCQB: RXMD), a personalized healthcare services and technology provider, is reporting financial results for the fiscal year ended Dec. 31, 2022. Highlights of the report include an increase in total revenue to $40.6 million, representing a 5% growth from the prior year, with pharmacy revenue increasing by $2.5 million, or 7%, and 340B contract revenue totaling $3.8 million for the year, an increase of $1 million from the year before. The company reported gross profit margin of approximately 24% in 2022, compared to approximately 26% in 2021, along with the completion of a capital raise with NextPlat Corp,…

Continue Reading

MondayApr 03, 2023 2:55 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies

BiondVax (NASDAQ: BVXV), which focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has shown, through an ongoing in vivo preclinical proof-of-concept study, that its lead NanoAb candidate for the treatment of COVID-19 exhibits clear competitive advantages over existing monoclonal antibodies (“mAbs”) and oral therapies. “According to statistically significant results released early January, BiondVax established that its inhaled therapy virtually eliminated the SARS-CoV-2 virus and prevented illness when administered prophylactically… The second set of results, announced January 23, evidenced that when the NanoAb was administered by inhalation three hours before infection,…

Continue Reading

MondayApr 03, 2023 12:59 pm

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Q4 and FY 2022 Financial Results

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced results for the fourth quarter and year ended Dec. 31, 2022. Among the highlights, the company reported $6,196,743 in revenues compared to $2,876,273 for the year ended Dec. 31, 2021. “I am extremely pleased with how far we have come in such a short time,” said Brian John, CEO of Jupiter Wellness. “In 2022, we shifted out of the CBD space and acquired and established new unique IP and products with little competition. We look forward to focusing on selling our brands and becoming profitable…

Continue Reading

MondayApr 03, 2023 12:41 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces FY 2022 Results, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released its financial results for the full year ended Dec. 31, 2022. The company also provided a clinical update of its anti-cancer drug candidate currently in development for the treatment of primary and metastatic brain and CNS cancer. “Over the course of 2022, we made significant advancements in our ongoing clinical trial for Berubicin. We have expanded our clinical trial sites across Europe and continued with an encouraging and increasingly rapid pace of…

Continue Reading

FridayMar 31, 2023 4:00 pm

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW), Jupiter Wellness Acquisition Corp. Schedule Special Meeting for Approval of Proposed Business Combination

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair, skin, and sexual wellness, is reporting that the U.S. Securities and Exchange Commission ("SEC") has declared effective its registration statement. Jupiter Wellness, the business combination sponsor, observed that the registration statement was regarding Chijet Motor Company Inc., a developer of next-generation electric vehicles, in connection with a previously announced proposed business combination with Jupiter Wellness Acquisition Corp. (NASDAQ: JWAC), a special purpose acquisition company. A special meeting of Jupiter Wellness Acquisition Corp. shareholders has been scheduled for April 20, 2023, to approve the proposed combination; the business combination is expected…

Continue Reading

FridayMar 31, 2023 1:47 pm

BioMedNewsBreaks – Apollomics Inc. (NASDAQ: APLM) Closes on Business Combination, Begins Trading

Apollomics (NASDAQ: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, has completed its business combination with Maxpro Capital Acquisition Corp. (NASDAQ: JMAC). According to the announcement, the company anticipated its class A ordinary shares and public warrants to commence trading on March 30, 2023, on the Nasdaq Capital Market. Apollomics is committed to improve treatment options for patients diagnosed with difficult-to-treat, high- mortality cancers. “Becoming a public company represents a major milestone in our journey to provide solutions for patients with difficult-to-treat cancers worldwide,” said Apollomics chair and CEO Dr. Guo-Liang Yu, PhD,…

Continue Reading

ThursdayMar 30, 2023 2:28 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Poised to Offer Timely Solution amid a ‘Smoldering Public Health Crisis’

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector electrocardiogram for heart attack detection anytime, anywhere. “A recent study shows that risk factors for cardiovascular (‘CV’) disease are rising among young adults… ‘Yet medical treatment rates for CV risk factors are ‘surprisingly low among young adults,’ study investigator Rishi Wadhera, MD, with Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, told theheart.org/Medscape Cardiology. In the article, Wadhera noted that the findings are ‘extremely concerning.’ He stated that ‘we’re witnessing a smoldering public health crisis. The onset of these risk factors…

Continue Reading